Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 91, Issue 2, 2015, Pages 344-350

  Koshy, Matthew ^a,b   Malik, Renuka ^b   Weichselbaum, Ralph R ^a,b   Sher, David J ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c RUSH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; DISEASES; HAZARDS; PATIENT TREATMENT; TUMORS;

BIOLOGICALLY EFFECTIVE DOSE; COMPARATIVE EFFECTIVENESS; INTER QUARTILE RANGES; METHODS AND MATERIALS; MULTIVARIABLE ANALYSIS; NON SMALL CELL LUNG CANCER; PROPORTIONAL HAZARDS; STEREOTACTIC BODY RADIATION THERAPY;

RADIOTHERAPY;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; EARLY CANCER; FEMALE; HUMAN; LARGE CELL LUNG CARCINOMA; LOW ENERGY RADIATION; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; SQUAMOUS CELL LUNG CARCINOMA; STEREOTACTIC BODY RADIATION THERAPY; YOUNG ADULT; CARCINOMA, NON-SMALL-CELL LUNG; EPIDEMIOLOGY; LUNG NEOPLASMS; MORTALITY; PATHOLOGY; PREVALENCE; RADIOSURGERY; REGISTER; RELATIVE BIOLOGIC EFFECTIVENESS; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; RADIOSURGERY; RADIOTHERAPY DOSAGE; REGISTRIES; RELATIVE BIOLOGICAL EFFECTIVENESS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84922455694     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.10.002     Document Type: Article

References (25)

1. Kelsey CR, Salama JK. Stereotactic body radiation therapy for treatment of primary and metastatic pulmonary malignancies. Surg Oncol Clin N Am 2013;22:463-481.
2. Zimmermann F, Wulf J, Lax I, et al. Stereotactic body radiation therapy for early non-small cell lung cancer. Front Radiat Ther Oncol 2010;42:94-114.
3. Palma D, Visser O, Lagerwaard FJ, et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: A population-based time-trend analysis. J Clin Oncol 2010;28:5153-5159.
4. Davis JN, Medbery C 3rd, Sharma S, et al. The RSSearch registry: Patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy. Radiat Oncol 2013;8:275.
5. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009;27:3290-3296.
6. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: Four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009;75:677-682.
7. Hadziahmetovic M, Loo BW, Timmerman RD, et al. Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancerdupdates of radiobiology, techniques, and clinical outcomes. Discov Med 2010;9:411-417.
8. Hara R, Itami J, Kondo T, et al. Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors. Cancer 2006;106:1347-1352.
9. Takeda A, Sanuki N, Kunieda E, et al. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys 2009;73:442-448.
10. Stephans KL, Djemil T, Reddy CA, et al. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: The Cleveland Clinic experience. J Thorac Oncol 2009;4:976-982.
11. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2(7 Suppl. 3):S94-S100.
12. Sura S, Yorke E, Jackson A, et al. High-dose radiotherapy for the treatment of inoperable non-small cell lung cancer. Cancer J 2007;13:238-242.
13. Olsen JR, Robinson CG, El Naqa I, et al. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;81:e299-e303.
14. Kestin L, Grills I, Guckenberger M, et al. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance. Radiother Oncol 2014;110:499-504.
15. National Cancer Data Base. Home page. Available at: www.facs.org/cancer/ncdb/. Accessed January 29, 2014.
16. Nuttall M, van der Meulen J, Emberton M. Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery. J Clin Epidemiol 2006;59:265-273.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
18. Mutter RW, Liu F, Abreu A, et al. Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer. Int J Radiat Oncol Biol Phys 2012;82:1783-1790.
19. Stephans KL, Djemil T, Tendulkar RD, et al. Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT). Int J Radiat Oncol Biol Phys 2012;82:974-980.
20. Mehta N, King CR, Agazaryan N, et al. Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent dose and local control. Pract Radiat Oncol 2012;2:288-295.
21. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076.
22. Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010;76:326-332.
23. Kirkpatrick JP, Meyer JJ, Marks LB. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol 2008;18:240-243.
24. Song CW, Cho LC, Yuan J, et al. Radiobiology of stereotactic body radiation therapy/stereotactic radiosurgery and the linear-quadratic model. Int J Radiat Oncol Biol Phys 2013;87:18-19.
25. Casamassima F, Masi L, Bonucci I, et al. Relevance of biologically equivalent dose values in outcome evaluation of stereotactic radiotherapy for lung nodules. Int J Radiat Oncol Biol Phys 2008;71:145-151.